Articles By Cyndi Root

  1. FDA Grants Orphan Drug Status To Bio Blast's Cabaletta For Spinocerebellar Ataxia Type 3 11/24/2014

    Bio Blast Pharma announced in a press release that the Food and Drug Administration (FDA) has granted Orphan Drug status to Cabaletta in the treatment of Spinocerebellar Ataxia type 3, the second Orphan designation for Cabaletta.

  2. FDA Fast Tracks Merrimack's, Baxter's MM-398 For Pancreatic Cancer 11/24/2014

    Merrimack Pharmaceuticals announced in a press release that the Food and Drug Administration (FDA) has granted MM-398 (nanoliposomal irinotecan injection) Fast Track designation.

  3. Basilea's BAL101553, Radiotherapy Delays Tumor Growth 11/24/2014

    Compared to BAL101553 monotherapy, Basilea’s investigational agent combined with radiotherapy significantly delays tumor growth.

  4. Vaccine & Gene Therapy Institute, TapImmune Partner On Cancer Vaccines 11/21/2014

    The Vaccine & Gene Therapy Institute of Florida (VGTI), a non-profit research institute, and TapImmune have formed a partnership to develop TapImmune’s cancer vaccines.

  5. ADC Market To Reach $3 Billion By 2018, Report Finds 11/19/2014

    According to a new report from Research and Markets, Antibody drug conjugates (ADCs) are so effective against cancer, that the global market for the agents will reach $3 billion by 2018.

  6. Presage Biosciences, Takeda Expand Partnership To Identify Oncology Drug Combinations 11/18/2014

    Presage Biosciences, an oncology company in Seattle, has expanded its partnership with Takeda and its subsidiary Millenium Pharmaceuticals.

  7. Amgen, AstraZeneca Report Phase 3 Brodalumab Meets Endpoints In Psoriasis 11/18/2014

    Amgen and AstraZeneca report that a Phase 3 trial of brodalumab has met its primary endpoint and all secondary endpoints in the treatment of moderate-to-severe plaque psoriasis.

  8. Gilead's Sovaldi Effective In Combination For HCV, Studies Find 11/17/2014

    Gilead Sciences announced data from several studies of Sovaldi (sofosbuvir) in combination with other agents for the treatment of hepatitis (HCV) infection.

  9. FDA Grants Breakthrough Therapy Designation To Spark Therapeutics' SPK-RPE65 For Retinal Dystrophies 11/13/2014

    Spark Therapeutics announced in a press release that the Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to its lead candidate, SPK-RPE65.

  10. FDA Accepts Amgen's BLA For Evolocumab In High Cholesterol 11/13/2014

    Amgen states that the Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for evolocumab.